Growth factor levels in platelet-rich plasma and correlations with donor age, sex, and platelet count.

By G. Weibrich, W. Kleis, G. Hafner, W. Hitzler. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2002

641 citations recorded by the source corpus.

Subfields: Emergency Medical Services, Public Health, Environmental and Occupational Health, Urology

View Paper: https://www.semanticscholar.org/paper/16a0cf79de1eb2fbd97037919605df018cddc7ca

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Urology

1. D. M. Dohan Ehrenfest
2. P. Doglioli
3. G. Sammartino
4. G. M. de Peppo

Citations in the corpus

• Platelet-rich plasma preparation for regenerative medicine: optimization and quantification of cytokines and growth factors (2013, result): “Other authors reported similar values for TGF-β1: 120 pg/10(6) platelets [47], 240 pg/10(6) platelets [48] and 55.”
• Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part II: platelet-related biologic features. (2006, methodology): “These latter values were collected in the literature: — cPRP by cell separator: values of Weibrich et al.20 — cPRP by 3I PCCS protocol: values of Weibrich et al.21 — cPRP by Curasan protocol: values of Weibrich et al.21 for IGF-I and TGFb-1 and of Zimmermann et al.22 for PDGF-BB — cPRP by Friadent-S”
• Autologous platelets as a source of proteins for healing and tissue regeneration (2003, background): “One potential handicap is that platelet PDGF levels may vary between individuals and the need for pre-therapy dosing has been evoked (53).”
• Platelet lysates promote mesenchymal stem cell expansion: A safety substitute for animal serum in cell‐based therapy applications (2005, methodology): “…assay for MSC clinical applications by studying the effect of platelet growth factors obtained from platelet-rich plasma, as a substitute for FCS. Platelets are known to display many functions during tissue repair and to release multiple growth factors (Weibrich et al., 2002; Sanchez et al., 2003).”
• Slow release of growth factors and thrombospondin-1 in Choukroun's platelet-rich fibrin (PRF): a gold standard to achieve for all surgical platelet concentrates technologies (2009, methodology): “…in growth factor (Anitua et al. 2007, 2008), BTI Biotechnology Institute, Vitoria, Spain), Curasan PRP (Kleinostheim, Germany; Appel et al. 2002; Weibrich et al. 2002a), Fibrinet system (Cascade Medical Enterprises, Wayne, NJ, USA; Leitner et al. 2006), FriadentSchütze PRP (Mannheim, Germany;…”